Groowe Groowe / Newsroom / TAK
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

TAK News

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Hemofil M (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F

globenewswire.com
TAK PFE

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

businesswire.com
TAK PTGX

Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight

prnewswire.com
LIVN PTC UCB XENE AQST TAK BHVN KNOP VRTX SUPN GSK SNY MD

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

prnewswire.com
HELP TAK BMY PFE CMPS

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026

accessnewswire.com
JNJ TAK

Chemotherapy Induced Peripheral Neuropathy (CIPN) Treatment Market Report 2026-2032: Revenues to Grow by $750M at 8.64% CAGR

globenewswire.com
ABBV AMGN PFE BMY MRK REGN SNY TAK NVS GSK HRTX

Positive Phase 3 Data Demonstrate Potential for ENTYVIO ® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

businesswire.com
TAK

Sickle Cell Disease Competitive Landscape Report 2026: Comprehensive Analysis of Over 40 Companies and More Than 50 Drugs

globenewswire.com
NVS PFE AGIO CRSP TAK

U.S. Orphan Drug Market Report 2026: A $200 Billion Opportunity by 2031 - Indication, Company, Trial Phase, Marketed Status of 1400 Drugs, Drug Sales of 150 Drugs, Pricing and Dosage of 400 Drugs

globenewswire.com
BMY GILD JNJ SNY TAK AMGN AZN LLY MRK PFE REGN VRTX ABBV ALNY AMTX BIIB BMRN CRSP EXAS INCY IONS JAZZ NTLA PTC RGEN XOM

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

globenewswire.com
FATE INDP AMGN NKTR IBIO TAK SNY INMB CLMT VERX GTBP BHVN CHRS GSK BMY MRK ABBV AZN GILD LLY KYMR REGN SPRY